Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Ono Pharmaceutical Co stock

4528.T
JP3197600004
859650

Price

1,641.80
Today +/-
+0.02
Today %
+0.23 %

Ono Pharmaceutical Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Ono Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Ono Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Ono Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Ono Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Ono Pharmaceutical Co Stock Price History

DateOno Pharmaceutical Co Price
12/18/20241,641.80 undefined
12/17/20241,638.00 undefined
12/16/20241,672.00 undefined
12/13/20241,681.00 undefined
12/12/20241,713.00 undefined
12/11/20241,723.00 undefined
12/10/20241,720.50 undefined
12/9/20241,711.00 undefined
12/6/20241,736.50 undefined
12/5/20241,760.50 undefined
12/4/20241,745.00 undefined
12/3/20241,758.00 undefined
12/2/20241,733.00 undefined
11/29/20241,732.00 undefined
11/28/20241,725.50 undefined
11/27/20241,714.00 undefined
11/26/20241,732.00 undefined
11/25/20241,717.00 undefined
11/22/20241,747.50 undefined
11/21/20241,746.50 undefined
11/20/20241,745.00 undefined
11/19/20241,766.50 undefined

Ono Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Ono Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Ono Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Ono Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Ono Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Ono Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Ono Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Ono Pharmaceutical Co’s growth potential.

Ono Pharmaceutical Co Revenue, EBIT and net profit per share

DateOno Pharmaceutical Co RevenueOno Pharmaceutical Co EBITOno Pharmaceutical Co Net Income
2027e519.34 B undefined120.19 B undefined89.78 B undefined
2026e516.04 B undefined111.1 B undefined88.06 B undefined
2025e487.67 B undefined103.27 B undefined83.67 B undefined
2024502.67 B undefined160.05 B undefined127.98 B undefined
2023447.19 B undefined149.76 B undefined112.72 B undefined
2022361.36 B undefined110.56 B undefined80.52 B undefined
2021309.28 B undefined98.49 B undefined75.43 B undefined
2020292.42 B undefined77.45 B undefined59.7 B undefined
2019288.63 B undefined63.31 B undefined51.54 B undefined
2018261.84 B undefined57.95 B undefined50.28 B undefined
2017244.8 B undefined76.1 B undefined55.79 B undefined
2016160.28 B undefined30.39 B undefined24.98 B undefined
2015135.78 B undefined14.79 B undefined12.98 B undefined
2014143.25 B undefined26.42 B undefined20.35 B undefined
2013145.39 B undefined31.92 B undefined24.12 B undefined
2012145.78 B undefined37.9 B undefined24.36 B undefined
2011135.26 B undefined35.2 B undefined24.22 B undefined
2010135.99 B undefined39.84 B undefined27.88 B undefined
2009136.56 B undefined43.47 B undefined23.77 B undefined
2008145.9 B undefined52.29 B undefined35.05 B undefined
2007141.71 B undefined52.84 B undefined35.27 B undefined
2006148.67 B undefined56.94 B undefined36.09 B undefined
2005145.3 B undefined60.05 B undefined39.24 B undefined

Ono Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
109.74121.08131.89126.46121.34121.43127.35130.73133.35134.99139.38145.3148.67141.71145.9136.56135.99135.26145.78145.39143.25135.78160.28244.8261.84288.63292.42309.28361.36447.19502.67487.67516.04519.34
-10.338.93-4.11-4.050.074.872.662.011.233.254.252.32-4.682.95-6.40-0.42-0.547.78-0.26-1.48-5.2218.0552.736.9610.231.315.7716.8423.7512.41-2.995.820.64
84.9585.7685.1484.6184.5584.8384.4883.9583.4684.7785.5385.5485.3385.1285.7084.3984.6881.6980.1276.6377.1474.1274.0973.2375.0370.9672.9672.3374.1275.3974.7177.0172.7872.31
93.23103.84112.29107102.6103107.58109.75111.3114.44119.22124.29126.86120.63125.04115.24115.15110.5116.79111.41110.5100.64118.76179.27196.45204.81213.36223.71267.85337.13375.55000
18.3522.0125.2824.924.5127.7628.0422.3622.7625.6330.8539.2436.0935.2735.0523.7727.8824.2224.3624.1220.3512.9824.9855.7950.2851.5459.775.4380.52112.72127.9883.6788.0689.78
-19.9114.88-1.53-1.5613.261.04-20.261.7712.6320.3527.19-8.02-2.26-0.64-32.1917.30-13.110.57-0.99-15.63-36.2492.50123.36-9.872.5015.8426.336.7540.0013.53-34.625.241.95
----------------------------------
----------------------------------
615615634633633630625620610595589587587583571550544541530530530530.05530.04530.05518.43514.17504.04499.2496.53488.35480.04000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Ono Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Ono Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (B)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (B)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                             
116.08129.77139.55159.41183.99179.7196.46105.44110.1125.89115.25111.6115.93134.56144.85117.01113.22125.97125.77130.1443.248.8557.9164.785.7871.47100.42104.98116.97164.29204.6
12.5713.4610.411.0510.5532.9232.4737.0739.3238.0739.3243.5842.1242.0641.139.4731.6136.737.8537.8242.2435.3356.4468.1370.3967.8668.9674.0992.7108.36129.01
23.9926.2234.7224.1123.7500000000000000084.985.5780.585.1210.818.427.8810.187.096.047.06
6.316.966.946.617.486.858.578.729.759.2410.099.039.359.39.9710.0614.6313.0518.6423.4124.2325.8123.2325.3331.2932.8232.9139.1541.8244.8148.63
0.410.450.50.390.520.433.96.287.878.7314.2915.3614.7114.5116.1314.0222.3915.6619.9823.380.962.315.437.7411.214.0415.0619.2522.6921.624.31
159.35176.86192.12201.57226.27219.89241.4157.51167.04181.92178.96179.57182.1200.43212.05180.55181.84191.37202.24214.74195.53197.87223.57271.03209.46194.62225.22247.64281.27345.1413.6
36.137.4147.3550.0447.5448.7353.4555.553.0159.7761.8859.2255.7753.2251.2650.5450.0148.6247.9849.6359.1570.7580.0983.6694.32108.87114.63113.87112.13108.42104.75
22.5921.2422.8824.0920.6234.3534.64126.52112.0797.77161.59190.81257.27244.77207.52178.33190.63167.95168.69180.2189.37213.19183.38176.69188.92171.59137.78146.91125.15123.42121.26
1.431.441.140.960.380.280.250.250.220.20.140.090.020.020.020.020.020.020.020.0100000000000
2.172.282.482.482.5622.011.781.661.631.461.31.171.091.041.030.870.960.991.3822.6933.9138.3245.2455.7263.0666.4468.2964.7369.1357.29
0000000000000000000000000000000
5.126.136.686.636.97.2612.2815.7122.4721.369.028.288.15.285.4410.89.8615.5316.59.6119.238.8715.0840.8560.81116.92129.38168.73155.92236.36216.77
67.468.5180.5384.277.9892.63102.63199.76189.43180.73234.09259.7322.34304.38265.28240.72251.38233.07234.18240.83290.44326.72316.88346.43399.76460.44448.22497.79457.94537.34500.07
226.75245.37272.65285.77304.26312.52344.04357.27356.47362.65413.05439.27504.44504.81477.33421.27433.22424.44436.41455.57485.96524.59540.45617.46609.23655.06673.44745.43739.2882.44913.67
                                                             
17.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.3617.36
171717171717171717171717171717.0817.0817.0817.0817.0817.0817.0817.0817.117.1417.1817.217.2317.2317.2417.0817.46
107.65126.42148.21169.49190.38214.56246.27264.35282.83304.35330.3364.24392.29404.06421.28422.57430.87435.54425.79430.82456.81449.69452.98492.24459.99499.09524.6162.3644.75709.89768.18
000000-0.0100.02-0.01-0.01-0.010.020.05-0.02-0.2-0.17-0.27-0.280.070.671.170.810.720.610.680.46520.541.72.173.89
00000005.24-2-4.1513.3615.1239.2830.248.19-6.750.78-4.78-2.8513.8714.9544.58051.0467.4261.1747.5761.4149.5449.5349.3
142160.78182.57203.85224.74248.91280.62303.95315.21334.56378.01413.7465.94468.71463.89450.05465.92464.93457.1479.2506.87529.88488.26578.49562.54595.5607.22678.84730.59796.03856.19
32.492.572.923.034.2474.442.756.833.052.663.132.973.043.422.345.325.774.2410.843.789.797.135.626.36.47.648.998.0310.74
6.747.267.296.237.346.673.633.73.7544.093.994.374.123.973.883.964.084.264.39000000010.3910.8211.730
22.8723.9527.722.3520.5823.8618.8822.9119.918.3427.7420.7418.3720.7722.3918.1517.1416.7921.0217.0516.4830.9342.0775.3862.4576.4282.7484.0754.63112.4190.57
3.252.184.012.182.130.70000000000000000.030.040.030.08000000
0.130.110.081.0819.790.0519.990.050.010.010.010.0100000000.10.510.260.290.40.310.442.192.022.32.492.31
35.9835.9941.6534.7652.8735.5149.4931.0926.429.1734.927.425.8727.8629.4125.4623.4426.1931.0425.7927.823552.1982.9368.4783.1591.33104.1376.75134.66103.62
41.7741.6541.5340.4520.1920.130.20.240.140.140.10.080.020.020.020.020.010.010.010.130.490.340.530.550.321.776.177.036.56.686.55
000000000001.7318.7520.988.272.962.972.932.595.0711.160.890.881.021.051.061.051.010.981.01
76.946.96.716.477.9712.6120.6823.2917.4618.5816.4613.79.159.382.80.690.721.81.294.6612.8810.588.889.86.356.863.874.094.043.88
48.7748.5948.4347.1626.6628.112.820.9223.4417.5918.6818.2732.4730.1517.675.783.673.674.46.56.1514.381210.3211.149.1714.0911.9511.611.711.44
84.7584.5990.0881.9379.5263.6162.352.0149.8446.7653.5845.6758.345847.0731.2327.1129.8635.4532.2833.9749.3864.293.2579.6192.32105.42116.0888.35146.35115.06
226.76245.36272.65285.77304.26312.52342.92355.96365.04381.32431.59459.37524.28526.72510.96481.28493.03494.79492.54511.49540.84579.26552.45671.74642.15687.82712.64794.92818.94942.38971.26
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Ono Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Ono Pharmaceutical Co's financial health and stability.

Assets

Ono Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Ono Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Ono Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Ono Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
50.0842.7943.748.9654.9365.7959.7561.659.5140.2743.1436.940.0134.6629.4618.3133.2774.5463.9265.1479.7100.89105.03143.53
3.414.164.113.723.944.224.033.523.3833.013.053.012.855.116.16.537.829.2110.6214.2115.8217.7217.45
000000000000000000000000
-29.53-30.13-31.36-20.15-21.64-33.23-19.48-15.64-18.1-25.48-25.17-7.76-20.42-18-5.599.13-25.38-10.64-60.35-12.39-23.19-42.65-41.32-0.54
6.0112.626.37-0.43-0.6-7.93-4.37-10.8-8.286.730.31-2.39-0.96-3.85-0.55-1.96-1.582.732.943.413.44-0.08-19.6-0.83
360230145531010000214131315142776737074
32.9425.129.3924.1720.4232.6825.1918.6622.9920.8918.0813.6714.115.110.864.689.9311.4936.3718.4528.3634.0634.296.64
29.9729.4422.8232.136.6328.8539.9338.6836.5224.5321.329.821.6315.6628.4231.5812.8474.4515.7366.7774.1673.9861.83159.61
-7,153-8,355-8,240-6,389-9,440-2,769-1,174-1,131-1,592-1,508-3,211-1,294-2,023-4,577-12,857-31,118-14,082-24,079-29,838-29,602-22,445-20,293-12,277-14,497
-42.964.03-34.96-11.85-40.83-34.67-44.16-6.537.4330.7316.8811.12-0.137.176.93-12.7613.04-17.99-34.19-49.76-10.23-57.596.04-100.26
-35.8112.39-26.72-5.46-31.39-31.91-42.99-5.49.0332.2420.0912.411.8911.7519.7818.3627.126.09-4.35-20.1612.21-37.2918.32-85.76
000000000000000000000000
12-19,898-137-8-36-18-67-1-1-1-1-1-1224-517-506-355-409-359-445-2,358-2,296-2,560-2,733
19-11-10,085-10,337-121-1,682-37-11,770-12,045-26,563-13-10,779-9-8-42-33-49-22-38,773-1-29,584-3-30,007-1
-3,657-24,082-14,392-14,442-4,865-6,993-7,728-25,837-29,169-49,017-19,566-30,335-19,072-18,846-19,636-19,603-19,465-20,552-62,549-22,279-54,721-24,754-60,237-32,484
-2.00-2.00-3.00-4.00-4.00-4.00-4.00-4.00-5.00-5.00-4.00-3.00-5.00-6.00-4.00-4.00-2.00-5.00-3.00-5.00-4.00-6.00-4.00-8.00
-3,686-4,171-4,167-4,093-4,704-5,289-7,620-14,062-17,118-22,448-19,548-19,552-19,057-19,056-19,073-19,060-19,059-20,116-23,414-21,828-22,775-22,449-27,666-29,742
-16.669.41-26.535.79-9.09-12.83-11.936.3514.776.0318.6410.482.494.0515.78-0.686.2635.84-81.05-5.299.02-7.968.0727.02
22,81821,08714,57725,70827,18726,08238,75337,54834,93023,01718,09028,50119,61111,08515,565461-1,24050,371-14,11137,17251,71253,68449,552145,113
000000000000000000000000

Ono Pharmaceutical Co stock margins

The Ono Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Ono Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Ono Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Ono Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Ono Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Ono Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Ono Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Ono Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Ono Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Ono Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Ono Pharmaceutical Co Margin History

Ono Pharmaceutical Co Gross marginOno Pharmaceutical Co Profit marginOno Pharmaceutical Co EBIT marginOno Pharmaceutical Co Profit margin
2027e74.71 %23.14 %17.29 %
2026e74.71 %21.53 %17.06 %
2025e74.71 %21.18 %17.16 %
202474.71 %31.84 %25.46 %
202375.39 %33.49 %25.21 %
202274.12 %30.6 %22.28 %
202172.33 %31.84 %24.39 %
202072.96 %26.49 %20.42 %
201970.96 %21.93 %17.86 %
201875.03 %22.13 %19.2 %
201773.23 %31.09 %22.79 %
201674.09 %18.96 %15.58 %
201574.12 %10.9 %9.56 %
201477.14 %18.45 %14.21 %
201376.63 %21.95 %16.59 %
201280.12 %26 %16.71 %
201181.69 %26.03 %17.91 %
201084.68 %29.3 %20.5 %
200984.39 %31.83 %17.4 %
200885.7 %35.84 %24.02 %
200785.12 %37.29 %24.89 %
200685.33 %38.3 %24.27 %
200585.54 %41.32 %27 %

Ono Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Ono Pharmaceutical Co earnings per share therefore indicates how much revenue Ono Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ono Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ono Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ono Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ono Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ono Pharmaceutical Co Revenue, EBIT and net profit per share

DateOno Pharmaceutical Co Sales per ShareOno Pharmaceutical Co EBIT per shareOno Pharmaceutical Co Earnings per Share
2027e1,041.42 undefined0 undefined180.03 undefined
2026e1,034.78 undefined0 undefined176.58 undefined
2025e977.89 undefined0 undefined167.79 undefined
20241,047.15 undefined333.41 undefined266.6 undefined
2023915.7 undefined306.66 undefined230.82 undefined
2022727.78 undefined222.67 undefined162.16 undefined
2021619.56 undefined197.28 undefined151.09 undefined
2020580.15 undefined153.66 undefined118.45 undefined
2019561.36 undefined123.13 undefined100.24 undefined
2018505.06 undefined111.78 undefined96.99 undefined
2017461.84 undefined143.58 undefined105.26 undefined
2016302.4 undefined57.34 undefined47.13 undefined
2015256.16 undefined27.91 undefined24.48 undefined
2014270.28 undefined49.85 undefined38.4 undefined
2013274.33 undefined60.23 undefined45.51 undefined
2012275.05 undefined71.52 undefined45.96 undefined
2011250.01 undefined65.07 undefined44.77 undefined
2010249.97 undefined73.24 undefined51.25 undefined
2009248.28 undefined79.04 undefined43.21 undefined
2008255.51 undefined91.57 undefined61.38 undefined
2007243.07 undefined90.64 undefined60.5 undefined
2006253.27 undefined97 undefined61.48 undefined
2005247.53 undefined102.29 undefined66.84 undefined

Ono Pharmaceutical Co business model

Ono Pharmaceutical Co Ltd is a Japanese company specialized in the development and marketing of innovative medications. It has a long history, being founded in 1717. Originally, it was a Chinese medicine business, but since its establishment in 1924, Ono Pharmaceutical has focused on the development of modern medications. The company's business model is based on research and development of medications. Ono Pharmaceutical has several branches in different countries and works closely with research institutions and universities to develop groundbreaking medications. The company is committed to providing innovative therapies to patients worldwide. Ono Pharmaceutical specializes in several areas, including oncology, immunology, neurology, and diabetes. In oncology, the company has launched several medications, including Opdivo and Sprycel, used for the treatment of various forms of cancer. Opdivo is an immunooncological medication that shows great promise and is used worldwide. In immunology, Ono Pharmaceutical has developed a range of medications, including Nivolumab, used for the treatment of various autoimmune diseases such as rheumatoid arthritis. Ono Pharmaceutical has also developed medications for influenza and other types of infections. In the field of neurology, the company has developed medications used for pain treatment, including the compound Fauldopamine. Despite the discovery of Fauldopamine, which is considered suitable for pain treatment, no final decision has been made regarding the application of this medication. In diabetes research, Ono Pharmaceutical has developed various medications used for the treatment of diabetes, including Alogliptin and Canagliflozin. These medications help diabetics better control their blood sugar levels and alleviate the symptoms of this disease. Ono Pharmaceutical has also launched numerous products used in different areas, such as Desitin, a cream for the treatment of skin disorders, or Minon, a skincare line. The company places great importance on collaboration and innovation to provide highly effective medications to patients. Ono Pharmaceutical is committed to expanding its presence in the global market and developing further innovative therapies to improve people's lives. Ono Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Ono Pharmaceutical Co SWOT Analysis

Strengths

Ono Pharmaceutical Co Ltd boasts a strong research and development capability, allowing them to innovate and develop new pharmaceutical products. This enables the company to stay competitive in the market and address evolving healthcare needs.

The company offers a diverse range of pharmaceutical products across various therapeutic areas. This diversification helps to mitigate risks associated with any single product or therapeutic category, enhancing the company's stability and resilience in the market.

Ono Pharmaceutical Co Ltd has established a strong market presence in Japan, one of the largest pharmaceutical markets in the world. This gives the company a significant competitive advantage, as it can leverage its brand reputation and distribution networks to capitalize on domestic opportunities.

Weaknesses

Despite its strong position in Japan, Ono Pharmaceutical Co Ltd has limited international presence compared to some of its global competitors. This restricts their ability to fully capitalize on the potential of international markets and may hinder future growth.

The company's revenue is heavily dependent on a few key products, which poses a risk if any of these products face regulatory challenges, patent expirations, or stiff competition. This concentration of revenue puts Ono Pharmaceutical Co Ltd at higher risk of financial instability.

Opportunities

Ono Pharmaceutical Co Ltd has the opportunity to expand its presence in international markets, leveraging its expertise and product portfolio to capture market share outside of Japan. This diversification would create additional revenue streams and reduce dependency on a single market.

The pharmaceutical industry is continually evolving, and there is a constant demand for innovative therapies. By investing in research and development efforts for novel treatments, Ono Pharmaceutical Co Ltd can position itself at the forefront of medical advancements and gain a competitive edge.

Threats

The pharmaceutical industry is highly competitive, with numerous global and local players vying for market share. Ono Pharmaceutical Co Ltd faces the threat of intense competition from both established competitors and emerging companies, which could impact its market position and profitability.

The pharmaceutical industry is subject to rigorous regulations and compliance requirements, which can pose challenges in terms of product development, approval, and market access. Adapting to evolving regulatory standards is essential for Ono Pharmaceutical Co Ltd to maintain compliance and ensure business continuity.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Ono Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Ono Pharmaceutical Co historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Ono Pharmaceutical Co shares outstanding

The number of shares was Ono Pharmaceutical Co in 2023 — This indicates how many shares 488.353 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Ono Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Ono Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Ono Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Ono Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Ono Pharmaceutical Co stock splits

In Ono Pharmaceutical Co's history, there have been no stock splits.

Ono Pharmaceutical Co dividend history and estimates

In 2023, Ono Pharmaceutical Co paid a dividend amounting to 77 JPY. Dividend means that Ono Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Ono Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Ono Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Ono Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Ono Pharmaceutical Co Dividend History

DateOno Pharmaceutical Co Dividend
2027e86.15 undefined
2026e86.15 undefined
2025e86.14 undefined
202480 undefined
202377 undefined
202261 undefined
202155.5 undefined
202045 undefined
201945 undefined
201842.5 undefined
201740 undefined
201638 undefined
201536 undefined
201436 undefined
201336 undefined
201236 undefined
201136 undefined
201036 undefined
200936 undefined
200822.4 undefined
200723.5 undefined
200614.5 undefined
20052 undefined

Ono Pharmaceutical Co dividend payout ratio

In 2023, Ono Pharmaceutical Co had a payout ratio of 37.45%. The payout ratio indicates the percentage of the company's profits that Ono Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Ono Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Ono Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Ono Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Ono Pharmaceutical Co Payout Ratio History

DateOno Pharmaceutical Co Payout ratio
2027e37.36 %
2026e37.38 %
2025e37.44 %
202437.27 %
202337.45 %
202237.62 %
202136.73 %
202037.99 %
201944.89 %
201843.82 %
201738 %
201680.63 %
2015147.05 %
201493.77 %
201379.12 %
201278.35 %
201180.41 %
201070.26 %
200983.31 %
200836.51 %
200738.84 %
200623.59 %
20052.99 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Ono Pharmaceutical Co.

Ono Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/202451.39 35.87  (-30.21 %)2025 Q2
6/30/202458.03 52.79  (-9.02 %)2025 Q1
3/31/202451.9 37.53  (-27.68 %)2024 Q4
12/31/202371.38 75.74  (6.11 %)2024 Q3
9/30/202397.33 88.18  (-9.4 %)2024 Q2
6/30/202367.46 65.16  (-3.4 %)2024 Q1
3/31/202346.12 34.95  (-24.23 %)2023 Q4
12/31/202269.96 68.23  (-2.47 %)2023 Q3
9/30/202264.62 67.3  (4.14 %)2023 Q2
6/30/202262.25 60.37  (-3.02 %)2023 Q1
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Ono Pharmaceutical Co stock

Eulerpool World ESG Rating (EESG©)

92/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

77

Environment

Scope 1 - Direct Emissions
8,200
Scope 2 - Indirect emissions from purchased energy
10,400
Scope 3 - Indirect emissions within the value chain
28,200
Total CO₂ emissions
18,600
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees19.935
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Ono Pharmaceutical Co shareholders

%
Name
Stocks
Change
Date
3.72857 % Meiji Yasuda Life Insurance Company18,594,00003/31/2024
3.29423 % Shogakukai (Ono)16,428,00003/31/2024
3.23909 % Kakumeiso Company16,153,00003/31/2024
2.87159 % Nomura Asset Management Co., Ltd.14,320,311108,0009/30/2024
2.58291 % The Vanguard Group, Inc.12,880,69693,7009/30/2024
2.34151 % Mitsubishi UFJ Trust and Banking Corporation11,676,900-3,778,0507/22/2024
1.92145 % BlackRock Fund Advisors9,582,100987,9006/30/2023
1.73269 % MUFG Bank, Ltd.8,640,7407407/22/2024
1.62289 % BlackRock Japan Co., Ltd.8,093,200901,0006/30/2023
1.55989 % Aioi Nissay Dowa Insurance Co., Ltd.7,779,00003/31/2024
1
2
3
4
5
...
10

Ono Pharmaceutical Co Executives and Management Board

Mr. Akira Sagara

(65)
Ono Pharmaceutical Co President, Chief Executive Officer, Representative Director (since 2008)
Compensation 228 M

Mr. Toichi Takino

(55)
Ono Pharmaceutical Co Senior Managing Executive Officer, Chief Director of Research, Director

Mr. Toshihiro Tsujinaka

(59)
Ono Pharmaceutical Co Senior Managing Executive Officer, Chief Director of Business Strategy, Director

Mr. Satoshi Takahagi

Ono Pharmaceutical Co Managing Executive Officer, Chief Director of Sales, Senior Director of Primary (since 2023)

Mr. Kiyoaki Idemitsu

(59)
Ono Pharmaceutical Co Managing Executive Officer, Chief Director of Development, Director
1
2
3
4

Most common questions regarding Ono Pharmaceutical Co

What values and corporate philosophy does Ono Pharmaceutical Co represent?

Ono Pharmaceutical Co Ltd represents values of innovation, integrity, and commitment to improving human health. Their corporate philosophy focuses on putting patients first and striving for excellence in research and development. Ono Pharmaceutical aims to contribute to society by developing innovative medicines and therapeutic solutions. With a strong emphasis on compliance and ethical standards, the company actively engages in collaborations and partnerships to accelerate the discovery and development of novel therapies. Through their dedication to advancing healthcare and delivering value to stakeholders, Ono Pharmaceutical Co Ltd has established itself as a leading player in the pharmaceutical industry.

In which countries and regions is Ono Pharmaceutical Co primarily present?

Ono Pharmaceutical Co Ltd is primarily present in Japan.

What significant milestones has the company Ono Pharmaceutical Co achieved?

Ono Pharmaceutical Co Ltd has achieved several significant milestones. Notably, they received approval for Opdivo, an anti-cancer medication, from the U.S. Food and Drug Administration (FDA) in 2014. This approval marked a major breakthrough in cancer treatment, leading to increased survival rates for patients with lung cancer, melanoma, and renal cell carcinoma. Additionally, Ono Pharmaceutical Co Ltd successfully expanded Opdivo's indications for other cancers such as bladder cancer and liver cancer in subsequent years. Furthermore, the company has formed strategic partnerships with international pharmaceutical companies, further strengthening its position in the global market.

What is the history and background of the company Ono Pharmaceutical Co?

Ono Pharmaceutical Co Ltd is a renowned pharmaceutical company based in Japan. Established in 1712, the company has a long-standing history in the healthcare industry. Ono Pharma focuses on the research, development, and manufacturing of innovative drugs and therapeutic solutions. With a strong commitment to improving global health, the company has made significant contributions to the field of oncology, immunology, and central nervous system disorders. Ono Pharma has collaborated with various international partners to expand its reach and enhance its product portfolio. Continuously striving for excellence, Ono Pharmaceutical Co Ltd has emerged as a trusted name in the pharmaceutical sector with its dedication to advancing medical science and improving patient outcomes.

Who are the main competitors of Ono Pharmaceutical Co in the market?

The main competitors of Ono Pharmaceutical Co Ltd in the market include Takeda Pharmaceutical Co Ltd, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd, and Eisai Co Ltd.

In which industries is Ono Pharmaceutical Co primarily active?

Ono Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Ono Pharmaceutical Co?

The business model of Ono Pharmaceutical Co Ltd revolves around the research, development, manufacturing, and commercialization of innovative pharmaceutical products. As a leading Japanese pharmaceutical company, Ono focuses on the development of prescription drugs in various therapeutic areas, including oncology, immunology, and central nervous system disorders. Ono Pharmaceuticals' business model emphasizes a strong commitment to scientific excellence and collaboration with research institutions and other pharmaceutical companies. By continually investing in cutting-edge research and development, Ono aims to provide effective and safe medications to improve the quality of patients' lives globally.

What is the P/E ratio of Ono Pharmaceutical Co 2024?

The Ono Pharmaceutical Co P/E ratio is 6.16.

What is the P/S ratio of Ono Pharmaceutical Co 2024?

The Ono Pharmaceutical Co P/S ratio is 1.57.

What is the Quality Investing of Ono Pharmaceutical Co?

The Quality Investing for Ono Pharmaceutical Co is 9/10.

What is the revenue of Ono Pharmaceutical Co 2024?

The Ono Pharmaceutical Co revenue is 502.67 B JPY.

How high is the profit of Ono Pharmaceutical Co 2024?

The Ono Pharmaceutical Co profit is 127.98 B JPY.

What is the business model of Ono Pharmaceutical Co

Ono Pharmaceutical Co. Ltd is a Japanese pharmaceutical company specializing in the development and distribution of innovative medications for over 70 years. It is headquartered in Osaka and focuses on multiple areas including oncology, immunology, neurology, and infectious diseases. In the field of oncology, Ono has established a leading position in the Asian market and offers a range of innovative treatment options for various types of cancer such as breast, lung, and prostate cancer. Some of their well-known products include Opdivo, an immunotherapy for treating different tumors, and Kyprolis, a medication for multiple myeloma. In the field of immunology, Ono focuses on developing treatments for autoimmune diseases and inflammation. This includes products such as Nivolumab for treating melanoma and renal cancer, Ozanimod for multiple sclerosis, and Etrolizumab for Crohn's disease and ulcerative colitis. Their neurology department encompasses medications for treating conditions like schizophrenia, depression, Parkinson's, and epilepsy. Well-known products in this area include antipsychotics like Olanzapine and Aripiprazole, as well as antiepileptics like Rufinamide and Gabapentin. Ono is also actively involved in developing therapies to combat infectious diseases. Some products in this area include Symbicort for asthma treatment and Dulera, an inhalable corticosteroid for seasonal and perennial allergic rhinitis. Ono's business model is based on continuous research and development of innovative medications that meet the needs of patients and doctors. The company continuously invests in research and development to meet the demands of the fast-paced pharmaceutical industry. Strategic partnerships with other pharmaceutical companies and university research departments also aim to expand their product range. In addition to product development, Ono also invests in improving its manufacturing processes and distribution channels. The company closely collaborates with distribution partners to market its products in Japan and internationally. Ono operates several subsidiary companies, including Ono Pharma USA Inc. and Ono Pharma UK Ltd., to distribute its products worldwide. The company aims to achieve a global reach and constantly expands its international network through partnerships with other companies and academic institutions. Overall, Ono Pharmaceutical Co. Ltd is a leading pharmaceutical company specializing in the development and marketing of innovative medications in various fields. With a strong presence in the Asian market and a growing international reach, Ono remains an important player in the pharmaceutical industry.

What is the Ono Pharmaceutical Co dividend?

Ono Pharmaceutical Co pays a dividend of 61 JPY distributed over 2 payouts per year.

How often does Ono Pharmaceutical Co pay dividends?

Ono Pharmaceutical Co pays out a dividend 2 times a year.

What is the Ono Pharmaceutical Co ISIN?

The ISIN of Ono Pharmaceutical Co is JP3197600004.

What is the Ono Pharmaceutical Co WKN?

The WKN of Ono Pharmaceutical Co is 859650.

What is the Ono Pharmaceutical Co ticker?

The ticker of Ono Pharmaceutical Co is 4528.T.

How much dividend does Ono Pharmaceutical Co pay?

Over the past 12 months, Ono Pharmaceutical Co paid a dividend of 80 JPY . This corresponds to a dividend yield of about 4.87 %. For the coming 12 months, Ono Pharmaceutical Co is expected to pay a dividend of 86.14 JPY.

What is the dividend yield of Ono Pharmaceutical Co?

The current dividend yield of Ono Pharmaceutical Co is 4.87 %.

When does Ono Pharmaceutical Co pay dividends?

Ono Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Ono Pharmaceutical Co?

Ono Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Ono Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 86.14 JPY are expected. This corresponds to a dividend yield of 5.26 %.

In which sector is Ono Pharmaceutical Co located?

Ono Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ono Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ono Pharmaceutical Co from 12/1/2024 amounting to 40 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Ono Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Ono Pharmaceutical Co in the year 2023?

In the year 2023, Ono Pharmaceutical Co distributed 77 JPY as dividends.

In which currency does Ono Pharmaceutical Co pay out the dividend?

The dividends of Ono Pharmaceutical Co are distributed in JPY.

All fundamentals about Ono Pharmaceutical Co

Our stock analysis for Ono Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ono Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.